Traduction de «thromboembolism in women using oral » (Néerlandais → Français) :

Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing

(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral contraceptives
(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral

compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ
drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States

Use of combined oral contraceptives among women with migraine and
Use of combined oral contraceptives among women with

The use of Femara, an oral therapy for postmenopausal women with hormone sensitive breast cancer, has driven approximately 70% of overall aromatase inhibitor market segment growth around the world, particularly in the initial adjuvant (post-surgery) setting (Source: IMS Health Q4 2009).
L’utilisation de Femara, traitement par voie orale pour les femmes postménopausées atteintes d’un cancer du sein hormonodépendant, a représenté quelque 70% de la croissance mondiale du segment de marché de l’inhibiteur de l’aromatase, notamment en tant que traitement adjuvant (post-chirurgical) de première intention.

Naar D.M. Grabrick et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.
D’après D.M. Grabrick et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.